MenQuadfi FDA Approval History
Last updated by Judith Stewart, BPharm on June 24, 2020.
FDA Approved: Yes (First approved April 23, 2020)
Brand name: MenQuadfi
Generic name: meningococcal (groups A, C, Y, W) conjugate vaccine
Dosage form: Injection
Company: Sanofi
Treatment for: Meningococcal Disease Prophylaxis
MenQuadfi (meningococcal (groups A, C, Y, W) conjugate vaccine) is a MenACWY vaccine indicated for active immunization for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in individuals 2 years of age and older.
- MenQuadfi does not prevent Neisseria meningitidis serogroup B disease.
- MenQuadfi is administered as an intramuscular injection.
- In the U.S., the CDC recommends vaccination against meningococcal disease with the MenACWY vaccine at 11-12 years of age with a booster dose at 16 years of age.
- MenQuadfi should not be given to people who have had a severe allergic reaction after a previous dose of MenQuadfi, any of its ingredients, or another vaccine that contains tetanus toxoid.
- The most common side effects following a first dose of MenQuadfi included injection site pain (25.5%–45.2%), muscle ache (20.1%–35.6%), headache (12.5%–30.2%), and tiredness (14.5%–26.0%). In adolescents and adults receiving a MenQuadfi booster, similar rates of these reactions were observed.
Development timeline for MenQuadfi
| Date | Article |
|---|---|
| Apr 24, 2020 | Approval FDA Approves MenQuadfi (Meningococcal (Groups A, C, Y, W) Conjugate Vaccine) for Meningococcal (MenACWY) Vaccination |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.